Clinical trials
Cardiomyopathies clinical trials
Below are recruiting cardiomyopathies clinical trials, each written for real people, not researchers. We’re tracking 322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07081711Recruiting
Testing new heart MRI technology in volunteers
This study is testing a new way to take pictures of the heart using MRI. It is looking for healthy volunteers to help make sure the technology works correctly.
Cleveland, OhioAges 18 years+ - NCT07077005Recruiting
Can Mavacamten Help You Exercise More?
This study looks at whether taking mavacamten for at least 12 weeks helps people with a certain type of heart disease (hypertrophic obstructive cardiomyopathy) exercise better. You'll have tests to check your heart's function and safety during exercise.
Munich, BavariaAges 18–99 - NCT07050160Enrolling by invitation
Long-term follow-up after gene therapy for arrhythmogenic cardiomyopathy
This study follows participants who have already received the gene therapy LX2020 for a genetic heart condition called arrhythmogenic cardiomyopathy. It tracks their long-term safety and health outcomes, with no new treatment given.
Ann Arbor, MichiganAges 18–67 - NCT07052903RecruitingPhase 3
RNA therapy for ATTR amyloidosis with heart involvement
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
La Jolla, CaliforniaAges 18–85 - NCT07023614RecruitingPhase 2
Study of Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
La Jolla, CaliforniaAges 18 years+ - NCT07021963RecruitingPhase 2
Long-term safety study of HRS-1893 for hypertrophic cardiomyopathy
This study tests the long-term safety of the drug HRS-1893 in people with hypertrophic cardiomyopathy who have already been in a previous HRS-1893 study. It helps doctors learn more about how safe the drug is over time.
Beijing, Beijing MunicipalityAges 18–85 - NCT07006493Recruiting
Radiofrequency ablation for obstructive hypertrophic cardiomyopathy
This trial tests a new treatment that uses radiofrequency energy (similar to heat) to shrink the thickened heart muscle blocking blood flow. It is for people with obstructive hypertrophic cardiomyopathy who have symptoms despite medication and are not able or willing to have heart surgery.
Beijing, Beijing MunicipalityAges 18–80 - NCT06922851Recruiting
Protein filter therapy for dilated cardiomyopathy
This trial tests a protein filtering treatment (immunoadsorption) for people with dilated cardiomyopathy who have a specific antibody linked to heart damage. It aims to see if removing these antibodies can improve heart function.
Wuhan, HubeiAges 18–75 - NCT06431919Recruiting
Adding statin to carvedilol for cirrhosis with heart problems
This trial tests whether adding a statin (simvastatin) to the usual heart medication carvedilol helps people with both cirrhosis and a related heart problem live longer and avoid serious liver complications.
ChandigarhAges 18–65 - NCT06490250Recruiting
Breathing vs. movement exercises for hypertrophic cardiomyopathy
This study compares two types of gentle exercises—breathing muscle training and a traditional Chinese movement practice called Baduanjin—to see which helps people with hypertrophic cardiomyopathy feel better and improve their daily life. If you have a thickened heart muscle but are stable and have mild symptoms, you may be able to join.
IstanbulAges 18 years+ - NCT06634108RecruitingPhase 1/Phase 2
Genistein for heart failure from ATTR amyloid cardiomyopathy
This trial tests whether genistein, a plant-based supplement, can help people with a specific type of heart disease called ATTR amyloid cardiomyopathy. You might join if you have heart failure with reduced pumping function and this rare protein condition.
London, OntarioAges 40–80 - NCT06922994RecruitingPhase 2
Testing atorvastatin for arrhythmogenic cardiomyopathy
This trial tests if a common cholesterol medicine, atorvastatin, can slow the progression of arrhythmogenic cardiomyopathy, a genetic heart condition that can cause abnormal heart rhythms. If you have this condition, joining this study may help researchers find a new way to protect your heart.
Pavia, PVAges 18 years+ - NCT06930092Recruiting
Stents to improve heart function in heart failure
This study tests whether opening blocked heart arteries with stents can improve heart function in people with heart failure caused by coronary artery disease. It may be an option if your heart is weak and you have multiple blockages but no recent heart attack or dangerous rhythm.
Seoul, Chongno-guAges 19 years+ - NCT06920030Recruiting
Testing a new heart device for heart failure
This trial tests a new device that delivers a gentle electrical current to the heart to improve its pumping strength. It is for people with a certain type of heart failure caused by weak heart muscle, not a blocked artery.
Banja Luka, Republic of SrbskaAges 18–75 - NCT06902896RecruitingPhase 1/Phase 2
FAP iCDC therapy for advanced heart failure from dilated cardiomyopathy
This trial tests a new treatment called FAP iCDC for people with end-stage dilated cardiomyopathy, a type of heart muscle disease. It aims to see if this therapy is safe and helps improve heart function when standard medicines are no longer enough.
Hangzhou, ZhejiangAges 18–75 - NCT05888662Recruiting
Compare two catheter approaches to treat ventricular tachycardia
This study compares an “outer heart” catheter approach (epicardial) versus an “inner heart” approach (endocardial-only) to treat a dangerous heart rhythm called ventricular tachycardia. It aims to see which approach works better and is safest for people with ischemic heart disease who are having their first ablation.
BordeauxAges 18 years+ - NCT06775665Recruiting
Real-world study on hypertrophic cardiomyopathy in China
This study looks at how hypertrophic cardiomyopathy (HCM) affects people in China in real-world settings. It may help doctors understand the condition better and improve care for patients like you.
Hangzhou, ZhejiangAges 18 years+ - NCT06683872Enrolling by invitation
CT heart modeling for hypertrophic obstructive cardiomyopathy
This trial uses a special CT scan to create a 3D model of your heart's blood flow. It aims to see if this model can help doctors better predict how well treatments work for people with a thick heart muscle that blocks blood flow.
Hangzhou, ZhejiangAges 18–70 - NCT06679946Enrolling by invitationPhase 3
Study of Vutrisiran for heart condition from TTR amyloidosis
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
Phoenix, ArizonaAges 18 years+ - NCT06661876Recruiting
Heart radiation therapy for heart failure
This trial tests if a low dose of radiation to the heart can help people with advanced heart failure feel better and improve heart function. It is for patients whose heart failure is stable but severe, and who are already on the best medications.
LeuvenAges 18 years+ - NCT06641830Enrolling by invitation
Study of cardiomyopathy in children
This trial studies children with cardiomyopathy to better understand the condition. It's for children who have been diagnosed with cardiomyopathy and who do not have other major heart problems or serious issues with other organs.
Chengdu, SichuanAges Up to 18 years - NCT06635863Enrolling by invitationPhase 4
Steroids versus standard heart medications for heart inflammation
This study compares two treatment strategies for people with unexplained heart failure and irregular heartbeats caused by inflammation: one group gets standard heart medications plus an immune-suppressing steroid (prednisone), and the other gets standard medications alone. Doctors want to see whether adding steroids helps improve heart function and control dangerous heart rhythms.
Phoenix, ArizonaAges 18 years+ - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
La Jolla, CaliforniaAges 18–75 - NCT05769036Recruiting
Biventricular vs left bundle pacing for heart failure outcomes
This trial compares two types of heart pacing to see which improves outcomes for people with heart failure. It may help those who need pacing to better coordinate heartbeats and relieve symptoms.
TomskAges 18–80
Hear when a new Cardiomyopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cardiomyopathies?
- Yes. Clin2 currently lists 322 recruiting cardiomyopathies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cardiomyopathies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cardiomyopathies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.